In neurodegenerative diseases, inhibition of NEDP1 can promote the breakdown of abnormal SGs in ALS, providing justification for the use of anti-NEDP1-Nb as an attractive ALS therapeutic. Here, SENP8 is linked to amyotrophic lateral sclerosis.